NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation; Board on Health Care Services; National Cancer Policy Forum; Nass S, Johnson AF, Zhu J, et al., editors. Addressing Treatment Resistance in the Development of Cancer Immune Modulator Therapeutics: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2024 Jul 29.
Addressing Treatment Resistance in the Development of Cancer Immune Modulator Therapeutics: Proceedings of a Workshop.
Show details- AhR
aryl hydrocarbon receptor
- AI
artificial intelligence
- CAR T
chimeric antigen receptor T cell
- CD
cluster of differentiation
- COE
contribution of effect
- COVID-19
coronavirus disease of 2019
- ctDNA
circulating tumor DNA
- CTLA-4
cytotoxic T-lymphocyte-associated protein 4
- dMMR
deficient mismatch repair
- EHR
electronic health record
- FDA
U.S. Food and Drug Administration
- FNIH
Foundation for the National Institutes of Health
- GITR
glucocorticoid-induced tumor-necrosis-factor-related gene
- ICI
immune checkpoint inhibitor
- IDO1
indoleamine 2,3-dioxygenase-1
- irAE
immune-related adverse event
- JAK
Janus kinase
- LAG-3
lymphocyte activation gene-3
- LungMAP
Lung Cancer Master Protocol
- mCODE
Minimal Common Oncology Data Elements
- ML
machine learning
- MRD
minimal residual disease
- MRI
magnetic resonance imaging
- MSI-H
microsatellite instability-high
- NCI
National Cancer Institute
- NLP
natural language processing
- ORIEN
Oncology Research Information Exchange Network
- pCR
pathological complete response
- PD-1
programmed cell death receptor 1
- PD-L1
programmed cell death ligand 1
- PET
positron emission tomography
- RECIST
Response Evaluation Criteria in Solid Tumors
- RNA
ribonucleic acid
- SCNA
somatic copy number alteration
- TCR
T-cell receptor
- TMB-H
tumor mutational burden-high
- Acronyms and Abbreviations - Addressing Treatment Resistance in the Development ...Acronyms and Abbreviations - Addressing Treatment Resistance in the Development of Cancer Immune Modulator Therapeutics
Your browsing activity is empty.
Activity recording is turned off.
See more...